166 related articles for article (PubMed ID: 19996410)
1. Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor.
Pecquet C; Staerk J; Chaligné R; Goss V; Lee KA; Zhang X; Rush J; Van Hees J; Poirel HA; Scheiff JM; Vainchenker W; Giraudier S; Polakiewicz RD; Constantinescu SN
Blood; 2010 Feb; 115(5):1037-48. PubMed ID: 19996410
[TBL] [Abstract][Full Text] [Related]
2. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.
Chachoua I; Pecquet C; El-Khoury M; Nivarthi H; Albu RI; Marty C; Gryshkova V; Defour JP; Vertenoeil G; Ngo A; Koay A; Raslova H; Courtoy PJ; Choong ML; Plo I; Vainchenker W; Kralovics R; Constantinescu SN
Blood; 2016 Mar; 127(10):1325-35. PubMed ID: 26668133
[TBL] [Abstract][Full Text] [Related]
3. Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes.
Pecquet C; Diaconu CC; Staerk J; Girardot M; Marty C; Royer Y; Defour JP; Dusa A; Besancenot R; Giraudier S; Villeval JL; Knoops L; Courtoy PJ; Vainchenker W; Constantinescu SN
Blood; 2012 May; 119(20):4625-35. PubMed ID: 22378845
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine 201 is required for constitutive activation of JAK2V617F and efficient induction of myeloproliferative disease in mice.
Yan D; Hutchison RE; Mohi G
Blood; 2012 Aug; 120(9):1888-98. PubMed ID: 22837531
[TBL] [Abstract][Full Text] [Related]
5. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
Pardanani A; Hood J; Lasho T; Levine RL; Martin MB; Noronha G; Finke C; Mak CC; Mesa R; Zhu H; Soll R; Gilliland DG; Tefferi A
Leukemia; 2007 Aug; 21(8):1658-68. PubMed ID: 17541402
[TBL] [Abstract][Full Text] [Related]
6. Modulation of human thrombopoietin receptor conformations uncouples JAK2 V617F-driven activation from cytokine-induced stimulation.
Papadopoulos N; Pristavec A; Nédélec A; Levy G; Staerk J; Constantinescu SN
Blood; 2023 Nov; 142(21):1818-1830. PubMed ID: 37616564
[TBL] [Abstract][Full Text] [Related]
7. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
[TBL] [Abstract][Full Text] [Related]
8. Constitutive activation and oncogenicity are mediated by loss of helical structure at the cytosolic boundary of thrombopoietin receptor mutant dimers.
Defour JP; Leroy E; Dass S; Balligand T; Levy G; Brett IC; Papadopoulos N; Mouton C; Genet L; Pecquet C; Staerk J; Smith SO; Constantinescu SN
Elife; 2023 Jun; 12():. PubMed ID: 37338955
[TBL] [Abstract][Full Text] [Related]
9. A Phenotypic Screen for Small-Molecule Inhibitors of Constitutively Active Mutant Thrombopoietin Receptor Implicated in Myeloproliferative Neoplasms.
Ngo A; Koay AZ; Pecquet C; Diaconu CC; Ould-Amer Y; Huang Q; Kang C; Poulsen A; Lee MA; Jenkins D; Shiau A; Constantinescu SN; Choong ML
Comb Chem High Throughput Screen; 2016; 19(10):824-833. PubMed ID: 27748177
[TBL] [Abstract][Full Text] [Related]
10. JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms.
Pietra D; Casetti I; Da Vià MC; Elena C; Milanesi C; Rumi E
Am J Hematol; 2012 Jul; 87(7):746-7. PubMed ID: 22565617
[TBL] [Abstract][Full Text] [Related]
11. JAK2V617F Megakaryocytes Promote Hematopoietic Stem/Progenitor Cell Expansion in Mice Through Thrombopoietin/MPL Signaling.
Zhang Y; Lin CHS; Kaushansky K; Zhan H
Stem Cells; 2018 Nov; 36(11):1676-1684. PubMed ID: 30005133
[TBL] [Abstract][Full Text] [Related]
12. Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F- and MPLW515 L-positive myelofibrosis.
Schulze S; Stengel R; Jaekel N; Wang SY; Franke GN; Roskos M; Schneider M; Niederwieser D; Al-Ali HK
Genes Chromosomes Cancer; 2019 Nov; 58(11):747-755. PubMed ID: 31135094
[TBL] [Abstract][Full Text] [Related]
13. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
Pikman Y; Levine RL
Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
[TBL] [Abstract][Full Text] [Related]
14. Aberrant signal transduction pathways in myeloproliferative neoplasms.
Kota J; Caceres N; Constantinescu SN
Leukemia; 2008 Oct; 22(10):1828-40. PubMed ID: 18769448
[TBL] [Abstract][Full Text] [Related]
15. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis.
Marty C; Pecquet C; Nivarthi H; El-Khoury M; Chachoua I; Tulliez M; Villeval JL; Raslova H; Kralovics R; Constantinescu SN; Plo I; Vainchenker W
Blood; 2016 Mar; 127(10):1317-24. PubMed ID: 26608331
[TBL] [Abstract][Full Text] [Related]
16. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine-phosphorylated SOCS3 negatively regulates cellular transformation mediated by the myeloproliferative neoplasm-associated JAK2 V617F mutant.
Funakoshi-Tago M; Tsuruya R; Ueda F; Ishihara A; Kasahara T; Tamura H; Tago K
Cytokine; 2019 Nov; 123():154753. PubMed ID: 31255914
[TBL] [Abstract][Full Text] [Related]
18. JAK2 and MPL mutations in myeloproliferative neoplasms.
Koppikar P; Levine RL
Acta Haematol; 2008; 119(4):218-25. PubMed ID: 18566540
[TBL] [Abstract][Full Text] [Related]
19. Ligand-independent thrombopoietin mutant receptor requires cell surface localization for endogenous activity.
Marty C; Chaligné R; Lacout C; Constantinescu SN; Vainchenker W; Villeval JL
J Biol Chem; 2009 May; 284(18):11781-91. PubMed ID: 19261614
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of MPL W515L/K mutations in Taiwanese patients with Philadelphia-negative chronic myeloproliferative neoplasms.
Lieu CH; Shen YJ; Lai WC; Tsai WH; Hsu HC
J Chin Med Assoc; 2010 Oct; 73(10):530-2. PubMed ID: 21051030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]